Table 1.
Effect of treatment on growth rate across multiple cell lines. P-value is derived from a log-linear mixed-effects model assessing the impact of treatment based on longitudinal cell number data. Treatments include MT-ND5 mutations, TGFB1 incubation and supplementing uridine, and other_supplements. Other_supple-ments combine 1 mM sodium pyruvate, 1x non-essential amino acids and 1x GlutaMAX. Uridine treatment was supplemented with 50 μg/ml uridine.
| Cell line | Assay Day | Heteroplasmy | Treatment | P value |
|---|---|---|---|---|
|
| ||||
| HEK293 | 12 | 30 % | MT-ND5 mutations | 0.707 |
| HEK293 | 18 | 20 % | MT-ND5 mutations | 0.195 |
| HEK293 | 23 | 19 % | MT-ND5 mutations | 0.659 |
| HEK293 | 26 | 19 % | MT-ND5 mutations | 0.67 |
| HEK293 | 30 | 18 % | MT-ND5 mutations | 0.973 |
| MCF12A | 11 | 11 % | MT-ND5 mutations | 0.961 |
| MCF12A | 10 | 10 % | MT-ND5 mutations | 0.76668 |
| MCF12A | 10 | 10 % | TGFB1 | 0.00442 |
| MCF12A | 12 | 11 % | Uridine | 0.8234 |
| MCF12A | 12 | 11 % | Other_supplements | 0.5858 |
| MCF12A | 12 | 11 % | MT-ND5 mutations | 0.9277 |
| HeLa | 6 | 22 % | MT-ND5 mutations | 0.2815 |